Improving Standard Therapies

Dr. Brad Nelson (2003 and 2004 Research Grants)

Dr. Brad Nelson’s research hopes to improve popular prostate cancer treatments like hormone therapy and radiation. In March 2007, he published a study that showed for the first time that, in addition to fighting cancer themselves, these therapies also stimulate the body’s own immune system to fight tumours.

Dr. Nelson identified 21 specific antigens that are released by prostate tumours and attacked by the immune system. He is now using these antigens to develop a drug that can improve the immune-friendly effects of radiation and hormone therapy. Ultimately, this drug – which would be given to men before treatment - could be a cost effective way of making therapy more effective and help men live longer.




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
RFP: Content Development and Delivery of an Accredited Electronic Continuing Medical Education Course for Prostate Cancer Specialists

Prostate Cancer Canada invites applications from service providers interested in the development, promotion and delivery of an accredited electronic Continuing Medical Education course targeting prostate cancer specialists, including urologists.
More

Prostate Cancer Canada announces new President and CEO

Toronto, December 21, 2017 – After five successful years under the leadership and guidance of outgoing President and CEO, Rocco Rossi, Prostate Cancer Canada (PCC) is excited to announce the appointment of a most worthy successor in Peter Coleridge, past national CEO of the Canadian Mental Health Association and current national President and CEO of Big Brothers Big Sisters of Canada.
More

Université de Sherbrooke Researchers’ Findings Published in Cancer Research

Sherbrooke, November 16, 2017 – Prostate cancer, the most common cancer in men, affects one out of seven Canadian men.
More


Click here for news archive